{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-26-009416","form_type":"8-K","ticker":"ADCT","cik":"0001771910","company_name":"ADC Therapeutics SA","filed_at":"2026-06-24T13:00:38+00:00","discovered_at":"2026-06-24T13:02:01.348558+00:00","generated_at":"2026-06-24T13:02:22.527146+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ADC Therapeutics cuts 17% of workforce, expects $10M annual savings; pre-sBLA meeting in Aug 2026","bullets":["Workforce reduction of ~17% globally, expected to generate ~$10M annualized cost savings.","One-time pre-tax charges of ~$3M for severance and termination costs, mostly in Q2 2026.","Pre-sBLA meeting with FDA in August 2026 for ZYNLONTA in r/r DLBCL; sBLA submission planned for Q4 2026.","LOTIS-7 trial data anticipated by end of 2026; cash runway at least into 2028.","Reorganization driven by completion of LOTIS-5 and LOTIS-7 trials and operational efficiencies."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-26-009416","json":"https://secwatch.observer/filing/0000950103-26-009416.json","markdown":"https://secwatch.observer/filing/0000950103-26-009416.md","text":"https://secwatch.observer/filing/0000950103-26-009416.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326009416/0000950103-26-009416-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326009416/dp248849_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T13:02:22.527146+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}